Oracea ruling leaves Amneal waiting years

Amneal Pharmaceuticals has received a mixed verdict in patentinfringement proceedings with Galderma Laboratories over eight US patents shielding Oracea (doxycycline) 40mg capsules. The ruling means Amneal is forbidden from obtaining final abbreviated new drug application (ANDA) approval until at least one asserted patent expires in December 2025.